SurgVision: Operating more precisely
This spin-off from the Helmholtz Zentrum München provides a novel solution for image-guided surgery, initially in the oncology area, that displays live images of tumour tissue. Tiny tumour cell aggregates that would normally be overlooked are made visible using fluorescence-labelled antibodies and an imaging system that can transform fluorescent signals in into precise, real-time images – even when the cells are covered with body fluids or thin layers of healthy tissue.
The tumour is then easier to recognize and can be removed much more precisely and completely, dramatically reducing the number of second surgeries required.
Origin: Helmholtz Zentrum München
SurgVision was founded in August 2013 in Groningen and builds on the ork of Prof. Dr Vasilis Ntziachristos and his colleagues at the Helmholtz Zentrum München. After initial financing from investors BioGeneration Ventures II B.V. and DFZ Participaties B.V., clinical development was pursued in close cooperation with the Department of Surgical Oncology at the University Medical Center Groningen.
The company will be further expanded into an integrated research and development organization. A close cooperation has been forged with the Institute for Biological and Medical Imaging at the Helmholtz Zentrum München and the Technische Universität München, to promote technology development.